IN2012DN02968A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN02968A IN2012DN02968A IN2968DEN2012A IN2012DN02968A IN 2012DN02968 A IN2012DN02968 A IN 2012DN02968A IN 2968DEN2012 A IN2968DEN2012 A IN 2968DEN2012A IN 2012DN02968 A IN2012DN02968 A IN 2012DN02968A
- Authority
- IN
- India
- Prior art keywords
- present
- relates
- heterocyclic
- schizophrenia
- solvate
- Prior art date
Links
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 abstract 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25110109P | 2009-10-13 | 2009-10-13 | |
| EP09172872 | 2009-10-13 | ||
| PCT/EP2010/065160 WO2011045258A1 (en) | 2009-10-13 | 2010-10-11 | Condensed azine - derivatives for the treatment of diseases related to the acetylcholine receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN02968A true IN2012DN02968A (es) | 2015-07-31 |
Family
ID=42040651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2968DEN2012 IN2012DN02968A (es) | 2009-10-13 | 2010-10-11 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8841289B2 (es) |
| EP (1) | EP2488520B1 (es) |
| JP (1) | JP2013507417A (es) |
| KR (1) | KR20120100913A (es) |
| CN (1) | CN102666540A (es) |
| AU (1) | AU2010305825A1 (es) |
| BR (1) | BR112012008518A2 (es) |
| CA (1) | CA2776835A1 (es) |
| IN (1) | IN2012DN02968A (es) |
| MX (1) | MX2012004289A (es) |
| RU (1) | RU2012119488A (es) |
| WO (1) | WO2011045258A1 (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014001265A2 (pt) | 2011-07-29 | 2017-02-21 | Taisho Pharmaceutical Co Ltd | composto de amidina ou seu sal |
| EP2822656B1 (en) | 2012-03-07 | 2016-10-19 | Institute of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| AU2013264943B2 (en) * | 2012-05-22 | 2018-02-01 | King Abdullah University Of Science And Technology | Combination comprising parthenolide for use in the treatment of Alzheimer's Disease and other neurodegenerative disorders |
| AU2014320149A1 (en) | 2013-09-11 | 2016-04-07 | Institute Of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| WO2016034703A1 (en) | 2014-09-05 | 2016-03-10 | AbbVie Deutschland GmbH & Co. KG | Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases |
| CA2971413A1 (en) | 2014-12-16 | 2016-06-23 | Axovant Sciences Gmbh | Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors |
| TWI698436B (zh) | 2014-12-30 | 2020-07-11 | 美商佛瑪治療公司 | 作為泛素特異性蛋白酶７抑制劑之吡咯并及吡唑并嘧啶 |
| MA41291A (fr) | 2014-12-30 | 2017-11-07 | Forma Therapeutics Inc | Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer |
| JP2018504431A (ja) | 2015-02-05 | 2018-02-15 | フォーマ セラピューティクス，インコーポレイテッド | ユビキチン特異的プロテアーゼ７阻害物質としてのチエノピリミジノン |
| HK1248220A1 (zh) | 2015-02-05 | 2018-10-12 | Forma Therapeutics, Inc. | 喹唑啉酮和偶氮喹唑啉作为泛特丁胺蛋白酶7抑制剂 |
| HK1248221A1 (zh) | 2015-02-05 | 2018-10-12 | Forma Therapeutics, Inc. | 异噻唑啉酮类，吡唑并嘧啶酮类和吡咯并嘧啶酮作为泛蛋白特异性蛋白酶7抑制剂 |
| CN106146410B (zh) * | 2015-04-03 | 2018-10-12 | 中南大学 | 6-氨基-4(3h)-喹唑啉酮衍生物及其合成方法和用途 |
| CN106279211B (zh) * | 2015-06-03 | 2020-09-15 | 北京大学 | 一种噻唑并嘧啶酮化合物及其制备方法和应用 |
| MX2017016231A (es) | 2015-06-10 | 2018-11-29 | Axovant Sciences Gmbh | Compuestos de aminobencisoxazol como agonistas de receptores a7-nicotínicos de acetilcolina. |
| EP3334740A4 (en) | 2015-08-12 | 2019-02-06 | Axovant Sciences GmbH | GEMINAL SUBSTITUTED AMINOBENZISOXAZOLE COMPOUNDS AS AGONISTS OF ALPHA 7-NICOTINIC ACETYLCHOLINE RECEPTORS |
| PT3386591T (pt) | 2015-12-09 | 2020-10-01 | Cadent Therapeutics Inc | Moduladores de recetores nmda heteroaromáticos e suas utilizações |
| ES2950348T3 (es) | 2015-12-09 | 2023-10-09 | Novartis Ag | Moduladores de receptores NMDA de tienopirimidinona y usos de los mismos |
| WO2018119374A1 (en) | 2016-12-22 | 2018-06-28 | Cadent Therapeutics | Nmda receptor modulators and uses thereof |
| EA202190116A1 (ru) | 2018-06-27 | 2021-08-30 | Реборна Биосайенсиз, Инк. | Агент для профилактики или лечения спинальной мышечной атрофии |
| HU231414B1 (hu) | 2018-07-13 | 2023-08-28 | Richter Gedeon Nyrt. | Tiadiazin származékok |
| CN112566906B (zh) | 2018-07-26 | 2024-11-12 | 多曼治疗学公司 | 取代的喹唑啉酮衍生物和它们作为mglur4的正变构调节剂的用途 |
| IL280474B2 (en) | 2018-08-03 | 2023-09-01 | Cadent Therapeutics Inc | Heteroaromatic nmda receptor modulators and their uses |
| WO2021198191A1 (en) | 2020-03-30 | 2021-10-07 | Enyo Pharma | Quinazolinone derivatives and uses thereof for treating a cancer |
| EP4126847A1 (en) | 2020-03-30 | 2023-02-08 | ENYO Pharma | Quinazolinone derivatives and uses thereof for treating a cancer |
| WO2022047145A1 (en) | 2020-08-28 | 2022-03-03 | Arvinas Operations, Inc. | Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| CN112898290B (zh) * | 2021-01-29 | 2022-08-05 | 中南大学 | 异噁唑甲酰胺基-4(3h)-喹唑啉酮衍生物及其合成方法和用途 |
| EP4584258A1 (en) | 2022-09-07 | 2025-07-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
| WO2025176185A1 (zh) * | 2024-02-23 | 2025-08-28 | 海思科医药集团股份有限公司 | 一种braf抑制剂的制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0000540D0 (sv) | 2000-02-18 | 2000-02-18 | Astrazeneca Ab | New compounds |
| JP2005504730A (ja) * | 2001-04-20 | 2005-02-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｇｓｋ−３インヒビターとして有用な組成物 |
| WO2003062235A1 (en) * | 2002-01-17 | 2003-07-31 | Eli Lilly And Company | Modulators of acetylcholine receptors |
| GB0220581D0 (en) | 2002-09-04 | 2002-10-09 | Novartis Ag | Organic Compound |
| TW200536830A (en) * | 2004-02-06 | 2005-11-16 | Chugai Pharmaceutical Co Ltd | 1-(2H)-isoquinolone derivative |
| PT1910333E (pt) * | 2005-07-26 | 2013-08-01 | Sanofi Sa | Derivados de isoquinolona substituída com piperidinilo como inibidores da rho-cinase |
| ATE523500T1 (de) * | 2006-09-11 | 2011-09-15 | Organon Nv | Chinazolinon- und isochinolinon-acetamid-derivate |
| WO2008077555A2 (en) * | 2006-12-27 | 2008-07-03 | Sanofi-Aventis | Substituted isoquinolines and their use as rho-kinase inhibitors |
| JP2010229035A (ja) * | 2007-08-01 | 2010-10-14 | Taisho Pharmaceutical Co Ltd | ピリドピリミジン−４−オン誘導体 |
| WO2009062988A1 (en) * | 2007-11-14 | 2009-05-22 | Neurosearch A/S | Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives and their medical use |
| EP2249455A1 (en) | 2008-02-29 | 2010-11-10 | Techno Core International Co., Ltd. | Charging device and quality judging device of pack cell |
-
2010
- 2010-10-11 WO PCT/EP2010/065160 patent/WO2011045258A1/en not_active Ceased
- 2010-10-11 BR BR112012008518A patent/BR112012008518A2/pt not_active Application Discontinuation
- 2010-10-11 RU RU2012119488/04A patent/RU2012119488A/ru unknown
- 2010-10-11 IN IN2968DEN2012 patent/IN2012DN02968A/en unknown
- 2010-10-11 CA CA2776835A patent/CA2776835A1/en not_active Abandoned
- 2010-10-11 MX MX2012004289A patent/MX2012004289A/es not_active Application Discontinuation
- 2010-10-11 EP EP10771062.6A patent/EP2488520B1/en active Active
- 2010-10-11 AU AU2010305825A patent/AU2010305825A1/en not_active Abandoned
- 2010-10-11 CN CN2010800465507A patent/CN102666540A/zh active Pending
- 2010-10-11 KR KR1020127009340A patent/KR20120100913A/ko not_active Withdrawn
- 2010-10-11 JP JP2012533593A patent/JP2013507417A/ja active Pending
- 2010-10-11 US US13/501,587 patent/US8841289B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US8841289B2 (en) | 2014-09-23 |
| JP2013507417A (ja) | 2013-03-04 |
| EP2488520B1 (en) | 2015-09-02 |
| CN102666540A (zh) | 2012-09-12 |
| EP2488520A1 (en) | 2012-08-22 |
| US20120208796A1 (en) | 2012-08-16 |
| KR20120100913A (ko) | 2012-09-12 |
| RU2012119488A (ru) | 2013-11-20 |
| WO2011045258A1 (en) | 2011-04-21 |
| BR112012008518A2 (pt) | 2016-04-05 |
| AU2010305825A1 (en) | 2012-04-19 |
| MX2012004289A (es) | 2012-06-12 |
| CA2776835A1 (en) | 2011-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN02968A (es) | ||
| WO2011051490A3 (en) | Heterocyclic derivatives | |
| IN2014DN03206A (es) | ||
| TN2013000285A1 (en) | Novel heterocyclic derivatives and their use in the treatment of neurological disorders | |
| MX2009000531A (es) | Derivados heterociclicos fusionados y metodos de uso. | |
| MX2010007683A (es) | Derivados heterociclicos fusionados y metodos de uso como inhibidores de c-met. | |
| MX2014000341A (es) | Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades. | |
| PH12020550503A1 (en) | Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors | |
| WO2009050242A3 (de) | Heterocyclus-substituierte piperazino-dihydrothienopyrimidine | |
| MX2009006543A (es) | Compuestos heterociclicos y su uso en el tratamiento de la inflamacion, angiogenesis y cancer. | |
| MX2014015158A (es) | Derivados de piridinona y piridazinona. | |
| PH12012500622A1 (en) | Compounds for the treatment of dyslipidemia and related diseases | |
| MX2009010407A (es) | Derivados fluorados de deferiprona. | |
| WO2008023258A8 (en) | Piperidine derivatives | |
| MX2010002900A (es) | Derivados heterociclicos triciclicos. | |
| MX2010004686A (es) | Derivados heterociclicos. | |
| PH12015500012A1 (en) | Benzodioxole derivative and preparation method and use thereof | |
| MX2010012189A (es) | Derivados de quinuclidina como antagonistas del receptor m3 muscarinico. | |
| MX2009012518A (es) | Derivados de piperidina 4,4-disubstituidos. | |
| MX2009007038A (es) | Derivados de mononitrato de isosorbida para el tratamiento de trastornos intestinales. | |
| MX2010004620A (es) | Derivados de benzomorfolina y metodos de uso. | |
| MX2009005242A (es) | Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo. | |
| MX2009006757A (es) | Compuestos de 4-(heterociclil)alquil-n-(arilsulfonil) indol y su uso como ligandos de la 5-hidroxitriptamina6. | |
| PH12016500197B1 (en) | Biphenyl derivative and method for preparing same | |
| WO2013043744A3 (en) | Tricyclic compounds useful as neurogenic and neuroprotective agents |